Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis

Journal of Chemotherapy

Volumn 17, Issue 4, 2005, Pages 452-453

  Budakoglu, Burçin ^a,b   Abali, H ^a   Uncu, D ^a   Yildirim, N ^a   Oksuzoglu B ^a   Zengin, N ^a  

^a Ankara Numune Egitim ve Arastirma Hastanesi   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

Author keywords

Colorectal cancer; Hemodialysis; Irinotecan

Indexed keywords

IRINOTECAN;

ADULT; ARTICLE; BLOOD TOXICITY; CASE REPORT; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL SURGERY; DIARRHEA; DRUG TOLERANCE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; RECTUM BIOPSY; SIDE EFFECT;

EID: 24644464779     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.4.452     Document Type: Article

References (10)

1. Venook AP, Enders Klein C, Fleming G, et al. A phase and farmocokinetic study of irinotecan in patients with hepatic and renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003; 14: 1783-1790.
2. Shimida Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-913.
3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 2000; 343: 905-914.
4. Karaoglu A, Yalçin S, Tekuzman G, et al. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil- based chemotherapy: efficacy and prognostic factors. Tumori 2003; 89: 141-145.
5. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportif care versus supportif care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
6. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
7. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of on independent panel. J Clin Oncol 2001; 19: 3801-3807.
8. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with colorectal carcinoma. J Clin Oncol 1997; 15: 251-260.
9. Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A. Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to choronic renal failure. Oncologie 2002; 25: 60-63.
10. Johnson SW, O'dwyer PJ. Cisplatin and its analogues. In DeVita VT, Hellman S, Rosenberg SA (Eds). Cancer Principles and Practice of Oncology, 7th Edition, Lippincott Williams and Wilkins, Philadelphia, 2005: 344-356.